This is a routine motion-to-dismiss denial — the case survives but is far from resolution. Monitor for summary judgment motions and any settlement discussions, but this ruling alone is unlikely to move JNJ stock materially given the company's size and the interlocutory nature of the decision.
Price Chart
Executive Summary
A federal district court denied Johnson & Johnson's motion to dismiss a product liability lawsuit alleging that the company failed to warn consumers about the risk of breast cancer from its antipsychotic drug Risperdal. The ruling allows the case to proceed to discovery, but it is an interlocutory procedural ruling that does not determine liability or damages.
Court Ruling Details
Key Facts
- Court denied J&J's motion to dismiss all claims in a failure-to-warn lawsuit over Risperdal and breast cancer risk.
- Ruling is interlocutory — case proceeds to discovery; no liability or damages determined.
- Plaintiffs allege J&J failed to warn about breast cancer risk based on studies from 2002 and 2014 and 44 adverse event reports.
- Court found plaintiffs plausibly alleged claims were timely under the discovery rule and not preempted by federal law.
- Punitive damages claim was allowed to proceed at the pleading stage.
Financial Impact
Not quantified in the ruling. No damages awarded or pleaded amount stated in the opinion.
Risk Factors
- If plaintiffs eventually prevail, damages could be material, but no amount is stated in this ruling.
- Adverse discovery outcomes or class certification could increase settlement pressure.
- Risperdal litigation has been ongoing for years; this is one of many cases.
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-f1e3070392-JNJ |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | 8-K | $248.61 | awaiting T+60 | — | $268.38 (+7.95%) |
Sep 30, 2026 27d ago | Court Ruling | $258.66 | awaiting T+60 | — | $268.38 (+3.76%) |
Sep 24, 2026 4w ago | Court Ruling | $271.22 | awaiting T+60 | — | $268.38 (−1.05%) |
Sep 9, 2026 6w ago | Court Ruling | $266.35 | awaiting T+60 | — | $268.38 (+0.76%) |
Aug 18, 2026 9w ago | Insider Cluster | $273.41 | awaiting T+60 | — | $268.38 (−1.84%) |
Aug 14, 2026 10w ago | Insider Cluster | $262.37 | awaiting T+60 | — | $268.38 (+2.29%) |
Aug 7, 2026 11w ago | Insider Cluster | $261.81 | awaiting T+60 | — | $268.38 (+2.51%) |
Aug 7, 2026 11w ago | Court Ruling | $261.81 | awaiting T+60 | — | $268.38 (−2.51%) |
Aug 4, 2026 12w ago | 8-K | $254.93 | awaiting T+60 | — | $268.38 (+5.28%) |
Jul 22, 2026 13w ago | Court Ruling | $259.27 $255.56 | ▲ +1.43% | ▲ +4.83% | $268.38 (−3.51%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers